Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study
| العنوان: | Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study |
|---|---|
| المؤلفون: | Eric Zijlstra, Christoph Kapitza, Qianyi Zhang, Helle Linnebjerg, Juliana M. Bue-Valleskey, David E. Coutant, Jennifer Leohr, Tim Heise, Elizabeth Smith Labell, Mary Anne Dellva |
| المصدر: | Diabetes, Obesity & Metabolism |
| بيانات النشر: | Blackwell Publishing Ltd, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Blood Glucose, medicine.medical_specialty, Glucose control, type 1 diabetes, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, insulin analogues, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Pharmacokinetics, Internal medicine, Internal Medicine, medicine, pharmacodynamics, randomized trial, Humans, Hypoglycemic Agents, Insulin, In patient, Type 1 diabetes, Cross-Over Studies, Insulin Lispro, business.industry, Original Articles, medicine.disease, Crossover study, Postprandial, glycaemic control, Diabetes Mellitus, Type 1, Glucose, Original Article, Insulin absorption, business, pharmacokinetics |
| الوصف: | Aims To compare the pharmacokinetic (PK) and glucodynamic (GD) characteristics of ultra rapid lispro (URLi; Eli Lilly and Company, Indianapolis, Indiana), Fiasp® (Novo Nordisk, Bagsvaerd, Denmark), Humalog® (Eli Lilly and Company) and NovoRapid® (Novo Nordisk), in patients with type 1 diabetes (T1D). Materials and Methods This was a randomized, double‐blind, four‐period, crossover study, conducted in 68 patients with T1D. Patients received the same individualized subcutaneous dose of each study drug immediately prior to a liquid test meal. For comparison, 12 healthy subjects received the same test meal. Results URLi had a significantly faster insulin absorption compared to the other insulins tested. Early half‐maximal drug concentration was reached 13 minutes after administration of URLi, which was 6 minutes faster than Fiasp, 13 minutes faster than Humalog, and 14 minutes faster than NovoRapid (all P |
| اللغة: | English |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5389cfce7345fb4921d7a00fbf48d12cTest http://europepmc.org/articles/PMC7540588Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5389cfce7345fb4921d7a00fbf48d12c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|